Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04762979
Title Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Amanda Parkes
Indications

Her2-receptor negative breast cancer

Therapies

Alpelisib + Fulvestrant

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST